Psychopharmacology

Here's an update on which medications are on the horizon for the treatment of schizophrenia and PTSD.

From a groundbreaking new launch for PTSD in the United States to connections between antidepressant treatment and metabolic syndrome, here are highlights from the week in Psychiatric Times.

The data assess the extended efficacy of the treatment for up to 4 years.

Will this medication make me gain weight? Researchers analyzed response to antidepressant treatment as a predictor of incident metabolic syndrome in a cohort of patients with depression.

Here are some updates from the world of psychiatry throughout the month of December.

The experts weighed in on a wide variety of psychiatric issues for the December 2023 issue of Psychiatric Times.

From new guidelines for the utilization of artificial intelligence in health care to the efficacy of fish oil as a replacement for antidepressants, here are highlights from the week in Psychiatric Times.

From a new look at the famous STAR*D study to updates from the National Academy of Sciences Conference on Adult ADHD, here are highlights from the week in Psychiatric Times.

What are the cardiometabolic risks of polypharmacy with quetiapine and long-acting injectable paliperidone in patients with schizophrenia?

“This is the first study to assess the standalone drug effects of MM-120 in the absence of any psychotherapeutic intervention.”

Researchers performed a systematic review and meta-analysis of the effects of clozapine on cognitive function in patients with treatment-resistant schizophrenia.

From adjunctive cariprazine for the treatment of major depressive disorder to a new app for prescribing antidepressants and antipsychotics, here are highlights from the week in Psychiatric Times.

Researchers performed a double-blind, placebo-controlled pilot study of solriamfetol.

The Psymatic Treatment Optimizer facilitates selecting agents ranked by adverse-effect profile with consideration of patient preference and tolerance.

From dopamine detoxification for problem gaming to connections between bacteria and anxiety and depression, here are highlights from the week in Psychiatric Times.

What is new in research on bipolar disorder?

The experts weighed in on a wide variety of psychiatric issues for the November 2023 issue of Psychiatric Times.

Here are some updates from the world of psychiatry throughout the month of November.

The FDA’s decision is set for September 2024.

From neurological abnormalities in first-episode psychosis to psychiatric boarding in emergency departments, here are highlights from the week in Psychiatric Times.

"During the past 5 years has gabapentin retained its position as one of the top 10 drugs prescribed in the United States."

These results were instrumental in securing the FDA approval of the drug for the treatment of schizophrenia in adults in April 2023.

From sleep and neuroendocrine function following TBI to new phase 3 results from a clinical trial evaluating a promising new schizophrenia treatment, here are highlights from the week in Psychiatric Times.

Researchers performed a head-to-head trial of vortioxetine versus desvenalfaxine in patients with depression and partial response to SSRIs.

The trial’s results showed statistically significant reductions in all major symptom domains and secondary endpoints.